tissue repair is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
| Property | Value | Notes |
|---|---|---|
| Typical subjects | Rats and mice | Animal models |
| Common routes | Injection and oral | Route varies by study |
| Reported dose range | Microgram to milligram per kg | Not standardized across work |
| Frequent endpoints | Tissue repair, angiogenesis | Marker-dependent |
| Human evidence | Limited | Mostly small or preliminary studies |
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
If the incircle is tangent to the sides AB, BC, CD, DA at T1, T2, T3, T4 respectively, and if N1, N2, N3, N4 are the isotomic conjugates of these points with respect to the corresponding sides (that is, AT1 = BN1 and so on), then the Nagel point of the tangential quadrilateral is defined as the intersection of the lines N1N3 and N2N4. Both of these lines divide the perimeter of the quadrilateral into two equal parts. More importantly, the Nagel point N, the "area centroid" G, and the incenter I are collinear in this order, and NG = 2GI. This line is called the Nagel line of a tangential quadrilateral. In a tangential quadrilateral ABCD with incenter I and where the diagonals intersect at P, let HX, HY, HZ, HW be the orthocenters of triangles AIB, BIC, CID, DIA. Then the points P, HX, HY, HZ, HW are collinear.
== Function == Little gastrin I stimulates Parietal cell in the stomach to secrete Hydrochloric acid. It does this partly by binding directly to Cholecystokinin B receptor on parietal cells, and partly by triggering Enterochromaffin-like cell to release Histamine, which then acts on parietal cells. Beyond acid secretion, it also plays a role in gastric motility and then release of Pepsin and Intrinsic factor.
==== Magnetic resonance and radio-frequency pulses ==== A perturbation of nuclear spin orientations from equilibrium will occur only when an oscillating magnetic field is applied whose frequency νrf sufficiently closely matches the Larmor precession frequency νL of the nuclear magnetization. The populations of the spin-up and -down energy levels then undergo Rabi oscillations, which are analyzed most easily in terms of precession of the spin magnetization around the effective magnetic field in a reference frame rotating with the frequency νrf. The stronger the oscillating field, the faster the Rabi oscillations or the precession around the effective field in the rotating frame. After a certain time on the order of 2–1000 microseconds, a resonant RF pulse flips the spin magnetization to the transverse plane, i.e. it makes an angle of 90° with the constant magnetic field B0 ("90° pulse"), while after a twice longer time, the initial magnetization has been inverted ("180° pulse"). It is the transverse magnetization generated by a resonant oscillating field which is usually detected in NMR, during application of the relatively weak RF field in old-fashioned continuous-wave NMR, or after the relatively strong RF pulse in modern pulsed NMR.
== Dietary sources == Animal fats are complex mixtures of triglycerides, with lesser amounts of both the phospholipids and cholesterol molecules from which all animal (and human) cell membranes are constructed. Since all animal cells manufacture cholesterol, all animal-based foods contain cholesterol in varying amounts. Major dietary sources of cholesterol include red meat, egg yolks and whole eggs, liver, kidney, giblets, fish oil, shellfish, and butter. Human breast milk also contains significant quantities of cholesterol. Plant cells synthesize cholesterol as a precursor for other compounds, such as phytosterols and steroidal glycoalkaloids, with cholesterol remaining in plant foods only in minor amounts or absent. Some plant foods, such as avocado, flax seeds and peanuts, contain phytosterols, which compete with cholesterol for absorption in the intestines and reduce the absorption of both dietary and bile cholesterol. A typical diet contributes in the order of 0.2 grams of phytosterols, not enough to have a significant impact on blocking cholesterol absorption. The intake of phytosterols can be supplemented through the use of phytosterol-containing functional foods or dietary supplements that are recognized as having potential to reduce levels of LDL-cholesterol.
=== Roads, highways, and bridges === During his 2022 gubernatorial campaign, Moore said he did not support Governor Hogan's plan to widen portions of the Capital Beltway and Interstate 270 using high-occupancy toll lanes, saying that he would instead support a transit line alongside I-270 and a proposed transit line from Prince George's County to Charles County. Critics have accused Moore of flip-flopping on this stance after he told the Maryland Transit Opportunities that he would be willing to dedicate federal funds to the project, issuing a statement afterwards saying that he would be open to toll lanes if there were strong public consensus. In a radio interview with WAMU in July 2022, he said he preferred a "new type of proposal" for the I-270 toll lanes plan that included reversible lanes, increased transit, and greater collaboration with local "stakeholders." In August 2023, Moore requested $2.4 billion in federal funding to add managed lanes to parts of the Capital Beltway and I-270, and to rebuild the American Legion Memorial Bridge. In January 2026, after meeting with U.S. Transportation Secretary Sean Duffy, Moore reversed his approach to rebuilding the American Legion Memorial Bridge, agreeing to instead seek a public–private partnership to rebuild the bridge. In December 2023, facing a long-term budget shortfall, Moore announced a six-year plan to cut the state's transportation budget by $3.3 billion, or eight percent, including a $1.6 billion cut to "all major highway expansion construction projects" and a $652 million cut to transit expansion projects.
Sources: en.wikipedia.org
UPMC Shadyside is a nationally ranked, 520-bed non-profit, tertiary, teaching hospital located in the Shadyside neighborhood of Pittsburgh, Pennsylvania. UPMC Shadyside is a part of the University of Pittsburgh Medical Center (UPMC), and grouped in with the flagship UPMC Presbyterian. The hospital is near UPMC's flagship campus which houses Presbyterian and Montefiore. As the hospital is a teaching hospital, it is affiliated with University of Pittsburgh School of Medicine. The hospital has an emergency room to handle emergencies, with a rooftop helipad to transport critical patients to and from the hospital. UPMC Shadyside houses the flagship campus of the UPMC Hillman Cancer Center, a nationally ranked cancer hospital. UPMC Shadyside is part of UPMC's flagship medical entity and is located in Pittsburgh's Shadyside neighborhood, with 520 beds and nearly 1,000 primary care physicians. Founded in as the Pittsburgh Homeopathic Hospital, it changed its name to that of the neighborhood of Shadyside on May 12, 1938. Shadyside agreed to be bought by UPMC on June 5, 1996. UPMC Shadyside is home to the Hillman Cancer Center, home of the University of Pittsburgh Cancer Institute.
Because of the greater stability of thioacetals, the equilibrium lies on the side of the acetal. In contradistinction to the O,O‑acetal case, it is not needed to remove water from the reaction mixture in order to shift the equilibrium. S,O-Acetals are hydrolyzed a factor of 10,000 times faster than the corresponding S,S-acetals. Their formation follows analogously from the thioalcohol. Also their cleavage proceeds under similar conditions and predominantly through mercury(II) compounds in wet acetonitrile. For aldehydes, a temporary protection of the carbonyl group the presence of ketones as hemiaminal ions is shown below. Here it is applied, that aldehydes are very much more activated carbonyls than ketones and that many addition reactions are reversible.
=== As a neurotransmitter === Glycine is a neurotransmitter in the central nervous system with both inhibitory and excitatory roles. Specifically, it is an agonist at the inhibitory glycine receptor, and a co-agonist along with glutamate at the excitatory NMDA receptor. The glycine receptor is expressed throughout the CNS, but especially in the spinal cord, brainstem, and retina. When glycine receptors are activated, chloride enters the neuron via the receptor, causing an inhibitory postsynaptic potential (IPSP). Strychnine is a strong antagonist at ionotropic glycine receptors, whereas bicuculline is a weak one. Removal of glycine from inhibitory glycinergic synapses is hypothesized to be primarily mediated by glycine transporter 2. This glycine transporter protein is predominantly expressed in neurons, and occurs in the hindbrain and spinal cord. Glycine is a required co-agonist along with glutamate at the excitatory NMDA receptors. That is, these receptors only open their ion channels to let cations into the cell, when both glycine and glutamate are present, while the neuron is already somewhat depolarized. Removal of glycine from NMDA receptor-associated synapses is facilitated by glycine transporter 1, which is hypothesized to co-localize with NMDA receptors in the brain. This glycine transporter protein is predominantly expressed in glial cells, and occurs throughout the brain and spinal cord. The LD50 of glycine is 7930 mg/kg in rats (oral), high concentrations are known to cause marked hyperexcitability and neurotoxicity via the activation of NMDA receptors.
== Treatments == Prevention of keloid scars in patients with a known predisposition to them includes preventing unnecessary trauma or surgery (such as ear piercing and elective mole removal) whenever possible. Any skin problems in predisposed individuals (e.g., acne, infections) should be treated as early as possible to minimize areas of inflammation. Treatments (both preventive and therapeutic) available are pressure therapy, silicone gel sheeting, intra-lesional triamcinolone acetonide (TAC), cryosurgery (freezing), radiation, pulsed dye laser (PDL), interferon (IFN), fluorouracil (5-FU) and surgical excision as well as a multitude of extracts and topical agents. Appropriate treatment of a keloid scar is age-dependent: radiotherapy, anti-metabolites, and corticosteroids would not be recommended to be used in children, to avoid harmful side effects, like growth abnormalities. In adults, corticosteroids combined with 5-FU and PDL in triple therapy enhance results and diminish side effects. Cryotherapy (or cryosurgery) refers to the application of extreme cold to treat keloids. This treatment method is easy to perform, effective, safe, and has the least chance of recurrence. Surgical excision is currently still the most common treatment for a significant number of keloid lesions. However, when used as the solitary form of treatment, there is a large recurrence rate of between 70 and 100%. It has also been known to cause a larger lesion formation on recurrence.
Sources: en.wikipedia.org
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.
Frequently measured outcomes include wound healing, blood vessel growth, and tissue repair markers. Some work examines gastrointestinal protection. The choice of endpoint depends on the model used.
Different routes of administration and different animal models require different amounts. Studies also use varied timelines and measurement methods. This variation makes it difficult to combine results into a single standardized figure.
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.